Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

NICE consults on Alzheimer's disease drugs

Home > PJ (current issue) > News / NewsCentre | Search

PJ Online homeThe Pharmaceutical Journal
Vol 276 No 7385 p98
28 January 2006

This article
Reprint   Photocopy

  Acrobat Reader


News summary


NICE consults on Alzheimer's disease drugs

A revised draft of a National Institute for Health and Clinical Excellence review of Alzheimer's disease treatments is recommending that donepezil (Aricept), galantamine (Reminyl) and rivastigmine (Exelon) should be considered as options for patients with moderately severe disease only (patients with a score of between 10 and 20 points on the mini mental state examination).

NICE is consulting on the revised guidance, which does not endorse memantine (Ebixa) except as part of clinical studies.

Current guidance on donepezil, galantamine and rivastigmine recommends the use of these drugs for all patients. A review initially concluded that there was not enough evidence to support this. However, NICE asked the companies involved to look for evidence to support the view that the drugs may be more effective for certain groups of people. This new evidence has resulted in the revised draft guidance.

NICE now expects to issue final guidance to the NHS in July.

Back to Top

©The Pharmaceutical Journal

Citation: The Pharmaceutical Journal URI: 20016511

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now
  • Pathology and Therapeutics for Pharmacists

    Pathology and Therapeutics for Pharmacists

    An practical, integrated approach to the pathophysiological and pharmacotherapeutic principles underlying the treatment of disease.

    £54.00Buy now
  • Drugs and the Liver

    Drugs and the Liver

    Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

    £38.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Rate
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.